ErythroMer, a nanotechnology-based artificial red blood cell product, emulated normal red blood cell interactions with oxygen and nitric oxide, according to results of a proof-of-concept study presented at the ASH Annual Meeting and Exposition.
Once validated in human studies, this product could provide a life-saving alternative to blood transfusions for situations in which donated blood is scarce.
“One key goal is to advance field resuscitation of civilian trauma victims in remote settings and soldiers who are wounded in austere environments without access to timely evacuation,†Allan Doctor, MD, director of pediatric critical care medicine, professor of pediatrics and associate professor of biochemistry and molecular biophysics at Washington University in Saint Louis, said in a press release.